Advertisement
Table 1 Demographic, serological, clinical data and medication of patients treated with MMF or CYC compared to controls
| Demographic, serological, clinical data and medication | MMF | CYC | Controls |
|---|---|---|---|
| (number = 25) | (number = 20) | (number = 22) | |
| SLEDAI-2 k (points); median (range) | 8 (2 to 14) | 11 (0 to 16) | 9 (3 to 18) |
| gender female number (%) | 18 (72.0) | 14 (70.0) | 18 (81.8) |
| age (years); mean ± SD | 38 ± 13 | 34 ± 9 | 40 ± 14 |
| duration (years); median (range) | 9 (2 to 28)a | 4 (0 to 25)a | 10 (0 to 26) |
| age at initial diagnosis of SLE (years); mean ± SD | 27 ± 11 | 29 ± 10 | 29 ± 14 |
| medication | |||
| prednisone (mg/day); median (range) | 7.0 (2.5 to 15.0) | 10.0 (0.0 to 30.0) | 6.3 (0.0 to 100.0) |
| co-medication with antimalarials number (%) | 18 (72.0) | 12 (60.0) | 16 (72.7) |
| currently active manifestations number (%) | |||
| class III-V nephritis | 10 (40.0) | 12 (60.0) | 6 (27.3) |
| eGFR <60 ml/min | 7 (28.0) | 4 (20.0) | 3 (13.6) |
| C3c <0.9 g/L | 18 (72.0) | 14 (70.0) | 16 (72.7) |
| neuropsychiatric | 0 | 0 | 0 |
| mucocutaneous/cutaneous | 8 (32.0) | 8 (40.0) | 7 (31.8) |
| arthritis | 5 (20.0) | 0bb | 9 (40.9)bb |
| serositis | 1 (4.0) | 0 | 4 (18.2) |
| myositis | 1 (4.0) | 1 (5.0) | 1 (4.5) |
| autoantibodies number (%) | |||
| anti-dsDNA >7 U/ml | 21 (84.0) | 15 (75.0) | 20 (90.9) |
| anti-Ro >7 U/ml | 11 (44.0) | 10 (50.0) | 13 (59.1) |
| anti-La >7 U/ml | 4 (16.0) | 4 (20.0) | 4 (18.2) |
| anti-U1-RNP >5 U/ml | 11 (44.0) | 12 (60.0) | 8 (36.4) |
| anti-SM >5 U/ml | 7 (28.0) | 9 (45.0) | 4 (18.2) |
